Cytochrome P450 epoxygenase CYP2J2 and the risk of coronary artery disease

被引：44
|
作者：
Spiecker, Martin
Liao, James K.
机构：
[1] Brigham & Womens Hosp, Cambridge, MA 02139 USA
[2] St Josef Hosp Bochum, Dept Med 2, D-44791 Bochum, Germany
来源：
TRENDS IN CARDIOVASCULAR MEDICINE | 2006年 / 16卷 / 06期
关键词：
D O I：
10.1016/j.tcm.2006.04.001
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Cytochrome P450 (CYP) enzyme 2J2, an epoxygenase predominantly expressed in the heart, metabolizes arachidonic acid to biologically active eicosanoids. One of the CYP2J2 products, 11,12-epoxyeicosatrienoic acid, has several vasoprotective effects. A frequent promoter polymorphism of CYP2J2 decreases gene expression and is associated with coronary artery disease. This association supports the vascular protective role of CYP-derived eicosanoids in cardiovascular disease.
引用
收藏
页码：204 / 208
页数：5
相关论文
共 50 条
  • [21] Expression of vascular antiinflammatory eicosanoids producing cytochrome P450 2J2 (CYP2J2) is reduced by promoter single nucleotide polymorphism
    Spiecker, M
    Darius, H
    Friedl, H
    Soufi, M
    Schäfer, J
    Zeldin, DC
    Liao, J
    Hankeln, T
    Schmidt, ER
    EUROPEAN HEART JOURNAL, 2001, 22 : 151 - 151
  • [22] RISK OF HYPERTENSION AND CARDIOVASCULAR DISEASE IN PATIENTS WITH POLYMORPHISM IN CYTOCHROME P450 2J2
    Liao, James K.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2004, 97 : S21 - S21
  • [23] Expression of cytochrome P450 2J2 (CYP2J2) and soluble epoxide hydrolase (sEH) in labored versus non-labored human myometrium
    Singh, Paul
    Genochio, David
    Zhou, Jianping
    Jodicke, Cristiano
    Connell, Matthew
    Sharma, Mukut
    Maulik, Dev
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2014, 210 (01) : S387 - S388
  • [24] THE CYP2J2 G50T POLYMORPHISM AND THE RISK OF CORONARY ARTERY DISEASE IN HAN CHINESE POPULATION
    Fu Zhenyan
    Xie Xiang
    Ma Yitong
    Yang Yining
    Yuan Shan
    Wang Lei
    HEART, 2010, 96 : A26 - A26
  • [25] Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome p450 enzymes: Major roles for CYP2J2 and CYP3A
    Liu, Kwang-Hyeon
    Kim, Mi-Gyung
    Lee, Dong-Jun
    Yoon, Yune-Jung
    Kim, Min-Jung
    Shon, Ji-Hong
    Choi, Chang Soo
    Choi, Young Kil
    Desta, Zeuresenay
    Shin, Jae-Gook
    DRUG METABOLISM AND DISPOSITION, 2006, 34 (11) : 1793 - 1797
  • [26] Endocannabinoid Virodhamine Is an Endogenous Inhibitor of Human Cardiovascular CYP2J2 Epoxygenase
    Carnevale, Lauren N.
    Arango, Andres S.
    Arnold, William R.
    Tajkhorshid, Emad
    Das, Aditi
    BIOCHEMISTRY, 2018, 57 (46) : 6489 - 6499
  • [27] Cytochrome P450 epoxygenase-eNOS interactions
    Wang, DW
    Wang, H
    Lin, L
    Zeldin, DC
    DRUG METABOLISM REVIEWS, 2002, 34 : 33 - 33
  • [28] Cytochrome P450 2C19 polymorphism in Iranian patients with coronary artery disease
    Akhlaghi, Arash
    Shirani, Shahin
    Ziaie, Naghmeh
    Pirhaji, Omid
    Yaran, Majid
    Shahverdi, Golnoosh
    Sarrafzadegan, Nizal
    Khosravi, Alireza
    Khosravi, Elham
    ARYA ATHEROSCLEROSIS, 2011, 7 (03) : 106 - 110
  • [29] Arachidonic acid cytochrome P450 epoxygenase pathway
    Spector, Arthur A.
    JOURNAL OF LIPID RESEARCH, 2009, 50 : S52 - S56
  • [30] Endocannabinoids Anandamide and 2-Arachidonoylglycerol Are Substrates for Human CYP2J2 Epoxygenase
    McDougle, Daniel R.
    Kambalyal, Amogh
    Meling, Daryl D.
    Das, Aditi
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2014, 351 (03): : 616 - 627
12345